The proceeds will support the company’s activities with its ongoing clinical trial of i-FACTOR peptide enhanced bone graft for cervical spine applications. The financing will also help accelerate development of new products.
More Articles on Devices:
Orthopedic, Spine Device Companies Brace for 2.3% Tax Impact
Biovenus Opens Dutch Headquarters
Sens. Amy Klobuchar, Al Franken Seek to Delay Medical Device Tax
